About
Overview
Company Leadership
Science
Technology Platform
Scientific Publications
Pipeline
Overview
Piclidenoson
Namodenoson
CF602
Investor Information
Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Fillings
Corporate Governance
Shareholders Meetings
Contact Us
Directions
Can-Fite BioPharma
(TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and liver diseases.
Science
The company technology platform is based on the finding that the Gi protein coupled A3 adenosine receptor (A3AR) is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells. High A3AR expression levels are also
>> more...
Pipeline
Can-Fite has a number of drugs in various stages of research and development. The pipeline drugs are synthetic, highly specific agonists and an allosteric modulator, all target the A3 adenosine receptor. All drugs are orally bioavailable with an excellent
>> more...
Investor Information
>>
Press Releases
>>
Financial Information
